Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions



Status:Completed
Conditions:Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - 45
Updated:1/25/2018
Start Date:September 2009
End Date:September 2009

Use our guide to learn which trials are right for you!

A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions

The objective of this study was to prove the bioequivalence of Roxane Laboratories'
Tinidazole 500 mg Tablet under fed conditions.


Inclusion Criteria:

- No clinically significant abnormal findings on the physical examination, medical
history, or clinical laboratory results during screening

Exclusion Criteria:

- Positive test for HIV, Hepatitis B, or Hepatitis C.

- Treatment with known enzyme altering drugs.

- History of allergic or adverse response to tinidazole or any comparable or similar
product.
We found this trial at
1
site
11300 Richmond Avenue
Houston, Texas 77042
?
mi
from
Houston, TX
Click here to add this to my saved trials